Nanotechnology Now - Press Release: AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

Home > Press > AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc. will present an overview of the Company at the Bear Stearns 20th Annual Healthcare Conference at 9:00 a.m. ET on Tuesday, September 11, 2007. The conference is being held at the Grand Hyatt Hotel in New York.

AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

CAMBRIDGE, MA | Posted on September 5th, 2007

Dr. Pereira will also present a corporate overview at the UBS Global Life Sciences Conference at 1:30 p.m. ET on Wednesday, September 26, 2007. This conference is also being held at the Grand Hyatt Hotel in New York.

Live audio webcasts of these presentations will be accessible through the Investors section of the company's web site at http://www.amagpharma.com . Following the conferences, the audio webcasts will be archived on the AMAG Pharmaceuticals, Inc. web site until October 27, 2007.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s lead product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients.

Combidex®, the Company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the Company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti
617-498-3362

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: